This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (412)  • Contact me when this article is cited  Related Content  • Related articles  • Similar articles in this journal  Topic Collections  • Glaucoma  • Randomized Controlled Trial  • Articles for Residents  • Alert me on articles by topic  Social Bookmarking   What's this?

Results From the Early Manifest Glaucoma Trial

Anders Heijl, MD, PhD; M. Cristina Leske, MD, MPH; Bo Bengtsson, MD, PhD; Leslie Hyman, PhD; Boel Bengtsson, PhD; Mohamed Hussein, PhD; for the Early Manifest Glaucoma Trial Group

Arch Ophthalmol. 2002;120:1268-1279.

Objective  To provide the results of the Early Manifest Glaucoma Trial, which compared the effect of immediately lowering the intraocular pressure (IOP), vs no treatment or later treatment, on the progression of newly detected open-angle glaucoma.

Design  Randomized clinical trial.

Participants  Two hundred fifty-five patients aged 50 to 80 years (median, 68 years) with early glaucoma, visual field defects (median mean deviation, -4 dB), and a median IOP of 20 mm Hg, mainly identified through a population screening. Patients with an IOP greater than 30 mm Hg or advanced visual field loss were ineligible.

Interventions  Patients were randomized to either laser trabeculoplasty plus topical betaxolol hydrochloride (n = 129) or no initial treatment (n = 126). Study visits included Humphrey Full Threshold 30-2 visual field tests and tonometry every 3 months, and optic disc photography every 6 months. Decisions regarding treatment were made jointly with the patient when progression occurred and thereafter.

Main Outcome Measures  Glaucoma progression was defined by specific visual field and optic disc outcomes. Criteria for perimetric progression were computer based and defined as the same 3 or more test point locations showing significant deterioration from baseline in glaucoma change probability maps from 3 consecutive tests. Optic disc progression was determined by masked graders using flicker chronoscopy plus side-by-side photogradings.

Results  After a median follow-up period of 6 years (range, 51-102 months), retention was excellent, with only 6 patients lost to follow-up for reasons other than death. On average, treatment reduced the IOP by 5.1 mm Hg or 25%, a reduction maintained throughout follow-up. Progression was less frequent in the treatment group (58/129; 45%) than in controls (78/126; 62%) (P = .007) and occurred significantly later in treated patients. Treatment effects were also evident when stratifying patients by median IOP, mean deviation, and age as well as exfoliation status. Although patients reported few systemic or ocular conditions, increases in clinical nuclear lens opacity gradings were associated with treatment (P = .002).

Conclusions  The Early Manifest Glaucoma Trial is the first adequately powered randomized trial with an untreated control arm to evaluate the effects of IOP reduction in patients with open-angle glaucoma who have elevated and normal IOP. Its intent-to-treat analysis showed considerable beneficial effects of treatment that significantly delayed progression. Whereas progression varied across patient categories, treatment effects were present in both older and younger patients, high- and normal-tension glaucoma, and eyes with less and greater visual field loss.

From the Department of Ophthalmology, Malmö University Hospital, Malmö, Sweden (Drs Heijl, Bo Bengtsson, and Boel Bengtsson), and the Department of Preventive Medicine, State University of New York at Stony Brook (Drs Leske, Hyman, and Hussein).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati     What's this?

RELATED ARTICLES

Impact of Intraocular Pressure Reduction on Glaucoma Progression
Paul R. Lichter
JAMA. 2002;288(20):2607-2608.
EXTRACT | FULL TEXT  

Expectations From Clinical Trials: Results of the Early Manifest Glaucoma Trial
Paul R. Lichter
Arch Ophthalmol. 2002;120(10):1371-1372.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Reliability and Sensitivity of the TonoLab Rebound Tonometer in Awake Brown Norway Rats
Morrison et al.
IOVS 2009;50:2802-2808.
ABSTRACT | FULL TEXT  

Optic Nerve and Optic Radiation Neurodegeneration in Patients with Glaucoma: In Vivo Analysis with 3-T Diffusion-Tensor MR Imaging
Garaci et al.
Radiology 2009;0:2522081240.
ABSTRACT | FULL TEXT  

Interpretation of the glaucoma "landmark studies"
Wishart
Br. J. Ophthalmol. 2009;93:561-562.
FULL TEXT  

Genetic Risk for Primary Open-Angle Glaucoma Determined by LMX1B Haplotypes
Park et al.
IOVS 2009;50:1522-1530.
ABSTRACT | FULL TEXT  

Primary Open-Angle Glaucoma
Kwon et al.
NEJM 2009;360:1113-1124.
FULL TEXT  

Glaucoma Monitoring in a Clinical Setting: Glaucoma Progression Analysis vs Nonparametric Progression Analysis in the Groningen Longitudinal Glaucoma Study
Wesselink et al.
Arch Ophthalmol 2009;127:270-274.
ABSTRACT | FULL TEXT  

Detection of visual-field deterioration by Glaucoma Progression Analysis and Threshold Noiseless Trend programs
Diaz-Aleman et al.
Br. J. Ophthalmol. 2009;93:322-328.
ABSTRACT | FULL TEXT  

Predicting Progressive Glaucomatous Optic Neuropathy Using Baseline Standard Automated Perimetry Data
Demirel et al.
IOVS 2009;50:674-680.
ABSTRACT | FULL TEXT  

Preventing Glaucoma in a High-Risk Population: Impact and Observations of the Ocular Hypertension Treatment Study
Rhee
Arch Ophthalmol 2009;127:216-218.
FULL TEXT  

Effects of the Timolol-Dorzolamide Fixed Combination and Latanoprost on Circadian Diastolic Ocular Perfusion Pressure in Glaucoma
Quaranta et al.
IOVS 2008;49:4226-4231.
ABSTRACT | FULL TEXT  

Predictors of and Barriers Associated With Poor Follow-up in Patients With Glaucoma in South India
Lee et al.
Arch Ophthalmol 2008;126:1448-1454.
ABSTRACT | FULL TEXT  

Long-term efficacy and safety of bimatoprost for intraocular pressure lowering in glaucoma and ocular hypertension: year 4
Williams et al.
Br. J. Ophthalmol. 2008;92:1387-1392.
ABSTRACT | FULL TEXT  

Latent Asymmetric Intraocular Pressure as a Predictor of Visual Field Defects
Hong et al.
Arch Ophthalmol 2008;126:1211-1215.
ABSTRACT | FULL TEXT  

The additional yield of a periodic screening programme for open-angle glaucoma: a population-based comparison of incident glaucoma cases detected in regular ophthalmic care with cases detected during screening
Stoutenbeek et al.
Br. J. Ophthalmol. 2008;92:1222-1226.
ABSTRACT | FULL TEXT  

Canadian Glaucoma Study: 2. Risk Factors for the Progression of Open-angle Glaucoma
Chauhan et al.
Arch Ophthalmol 2008;126:1030-1036.
ABSTRACT | FULL TEXT  

Finding Risks for Glaucoma
Brandt
Arch Ophthalmol 2008;126:1138-1139.
FULL TEXT  

Glaucoma and Fitness to Drive: Using Binocular Visual Fields to Predict a Milestone to Blindness
Owen et al.
IOVS 2008;49:2449-2455.
ABSTRACT | FULL TEXT  

Effectiveness and Safety of Dorzolamide-Timolol Alone or Combined with Latanoprost in Open-Angle Glaucoma or Ocular Hypertension
Lesk et al.
The Annals of Pharmacotherapy 2008;42:498-504.
ABSTRACT | FULL TEXT  

Open-angle Glaucoma and Mortality: The Barbados Eye Studies
Wu et al.
Arch Ophthalmol 2008;126:365-370.
ABSTRACT | FULL TEXT  

Estimating the Rate of Progressive Visual Field Damage in Those with Open-Angle Glaucoma, from Cross-Sectional Data
Broman et al.
IOVS 2008;49:66-76.
ABSTRACT | FULL TEXT  

Optimizing Therapy for Newly Diagnosed Open-angle Glaucoma: Lessons Learned From the Collaborative Initial Glaucoma Treatment Study
Pasquale
Arch Ophthalmol 2008;126:125-127.
FULL TEXT  

Using Pharmacy Claims Data to Study Adherence to Glaucoma Medications: Methodology and Findings of the Glaucoma Adherence and Persistency Study (GAPS)
Friedman et al.
IOVS 2007;48:5052-5057.
ABSTRACT | FULL TEXT  

Long-term Intraocular Pressure Fluctuation and Progressive Visual Field Deterioration in Patients With Glaucoma and Low Intraocular Pressures After a Triple Procedure
Hong et al.
Arch Ophthalmol 2007;125:1010-1013.
ABSTRACT | FULL TEXT  

Severe Loss of Central Vision in Patients With Advanced Glaucoma Undergoing Trabeculectomy
Law et al.
Arch Ophthalmol 2007;125:1044-1050.
ABSTRACT | FULL TEXT  

Intraocular Pressure Fluctuation: An Independent Risk Factor for Glaucoma?
Caprioli
Arch Ophthalmol 2007;125:1124-1125.
FULL TEXT  

Evaluation of ocular surface temperature and retrobulbar haemodynamics by infrared thermography and colour Doppler imaging in patients with glaucoma
Galassi et al.
Br. J. Ophthalmol. 2007;91:878-881.
ABSTRACT | FULL TEXT  

Diurnal IOP control with bimatoprost versus latanoprost in exfoliative glaucoma: a crossover, observer-masked, three-centre study
Konstas et al.
Br. J. Ophthalmol. 2007;91:757-760.
ABSTRACT | FULL TEXT  

Knowledge, Attitudes, and Beliefs about Dilated Eye Examinations among African-Americans
Ellish et al.
IOVS 2007;48:1989-1994.
ABSTRACT | FULL TEXT  

Automated Segmentation of the Optic Disc from Stereo Color Photographs Using Physiologically Plausible Features
Abramoff et al.
IOVS 2007;48:1665-1673.
ABSTRACT | FULL TEXT  

Col4a1 mutation causes endoplasmic reticulum stress and genetically modifiable ocular dysgenesis
Gould et al.
Hum Mol Genet 2007;16:798-807.
ABSTRACT | FULL TEXT  

Effects of TGF-{beta}2, BMP-4, and Gremlin in the Trabecular Meshwork: Implications for Glaucoma
Wordinger et al.
IOVS 2007;48:1191-1200.
ABSTRACT | FULL TEXT  

Blood flow in glaucoma
Orgul
Br. J. Ophthalmol. 2007;91:3-5.
FULL TEXT  

Meta-analysis of randomised controlled trials comparing latanoprost with brimonidine in the treatment of open-angle glaucoma, ocular hypertension or normal-tension glaucoma
Fung et al.
Br. J. Ophthalmol. 2007;91:62-68.
ABSTRACT | FULL TEXT  

Tumor Necrosis Factor-{alpha} Mediates Oligodendrocyte Death and Delayed Retinal Ganglion Cell Loss in a Mouse Model of Glaucoma
Nakazawa et al.
J. Neurosci. 2006;26:12633-12641.
ABSTRACT | FULL TEXT  

Corneal Thickness- and Age-Related Biomechanical Properties of the Cornea Measured with the Ocular Response Analyzer
Kotecha et al.
IOVS 2006;47:5337-5347.
ABSTRACT | FULL TEXT  

SNPs and Interaction Analyses of Noelin 2, Myocilin, and Optineurin Genes in Japanese Patients with Open-Angle Glaucoma
Funayama et al.
IOVS 2006;47:5368-5375.
ABSTRACT | FULL TEXT  

Mutant Myocilin Nonsecretion In Vivo Is Not Sufficient To Cause Glaucoma
Gould et al.
Mol. Cell. Biol. 2006;26:8427-8436.
ABSTRACT | FULL TEXT  

Effect of beta radiation on success of glaucoma drainage surgery in South Africa: randomised controlled trial
Kirwan et al.
BMJ 2006;333:942.
ABSTRACT | FULL TEXT  

Concordance of Aqueous Humor Flow in the Morning and at Night in Normal Humans
Radenbaugh et al.
IOVS 2006;47:4860-4864.
ABSTRACT | FULL TEXT  

Intraocular pressure-lowering efficacy of bimatoprost 0.03% and travoprost 0.004% in patients with glaucoma or ocular hypertension
Cantor et al.
Br. J. Ophthalmol. 2006;90:1370-1373.
ABSTRACT | FULL TEXT  

A topical nitric oxide-releasing dexamethasone derivative: effects on intraocular pressure and ocular haemodynamics in a rabbit glaucoma model
Galassi et al.
Br. J. Ophthalmol. 2006;90:1414-1419.
ABSTRACT | FULL TEXT  

Relative Risk of Progressive Glaucomatous Visual Field Loss in Patients Enrolled and Not Enrolled in a Prospective Longitudinal Study
Henson and Shambhu
Arch Ophthalmol 2006;124:1405-1408.
ABSTRACT | FULL TEXT  

Glaucoma screening during regular optician visits: can the population at risk of developing glaucoma be reached?
Stoutenbeek and Jansonius
Br. J. Ophthalmol. 2006;90:1242-1244.
ABSTRACT | FULL TEXT  

Effect of latanoprost on the expression of matrix metalloproteinases and their tissue inhibitors in human trabecular meshwork cells.
Oh et al.
IOVS 2006;47:3887-3895.
ABSTRACT | FULL TEXT  

Twice-Daily 0.2% Brimonidine-0.5% Timolol Fixed-Combination Therapy vs Monotherapy With Timolol or Brimonidine in Patients With Glaucoma or Ocular Hypertension: A 12-Month Randomized Trial.
Sherwood et al.
Arch Ophthalmol 2006;124:1230-1238.
ABSTRACT | FULL TEXT  

Genomewide scan and fine mapping of quantitative trait Loci for intraocular pressure on 5q and 14q in west africans.
Rotimi et al.
IOVS 2006;47:3262-3267.
ABSTRACT | FULL TEXT  

Optic disc and visual field progression in ocular hypertensive subjects: detection rates, specificity, and agreement.
Strouthidis et al.
IOVS 2006;47:2904-2910.
ABSTRACT | FULL TEXT  

Effects of Topical Hypotensive Drugs on Circadian IOP, Blood Pressure, and Calculated Diastolic Ocular Perfusion Pressure in Patients with Glaucoma.
Quaranta et al.
IOVS 2006;47:2917-2923.
ABSTRACT | FULL TEXT  

The epidemiology of medical treatment for glaucoma and ocular hypertension in the United Kingdom: 1994 to 2003
Owen et al.
Br. J. Ophthalmol. 2006;90:861-868.
ABSTRACT | FULL TEXT  

Visual field defects and retinal ganglion cell losses in patients with glaucoma.
Harwerth and Quigley
Arch Ophthalmol 2006;124:853-859.
ABSTRACT | FULL TEXT  

Analysis of expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human ciliary body after latanoprost.
Oh et al.
IOVS 2006;47:953-963.
ABSTRACT | FULL TEXT  

Correlation of Asymmetric Glaucomatous Visual Field Damage and Water-Drinking Test Response
Susanna et al.
IOVS 2006;47:641-644.
ABSTRACT | FULL TEXT  

The rising cost of glaucoma drugs in Ireland 1996-2003
Knox et al.
Br. J. Ophthalmol. 2006;90:162-165.
ABSTRACT | FULL TEXT  

Visual Field Progression in Glaucoma: Total Versus Pattern Deviation Analyses
Artes et al.
IOVS 2005;46:4600-4606.
ABSTRACT | FULL TEXT  

Unsupervised Machine Learning with Independent Component Analysis to Identify Areas of Progression in Glaucomatous Visual Fields
Sample et al.
IOVS 2005;46:3684-3692.
ABSTRACT | FULL TEXT  

Screening for glaucoma
Harris
BMJ 2005;331:E376-E377.
FULL TEXT  

Mechanistic Insights into Glaucoma Provided by Experimental Genetics The Cogan Lecture
John
IOVS 2005;46:2650-2661.
FULL TEXT  

Glaucoma: Macrocosm to Microcosm The Friedenwald Lecture
Quigley
IOVS 2005;46:2663-2670.
FULL TEXT  

Treatment of ocular hypertension and open angle glaucoma: meta-analysis of randomised controlled trials
Maier et al.
BMJ 2005;331:134.
ABSTRACT | FULL TEXT  

A comparison of four methods of tonometry: method agreement and interobserver variability
Tonnu et al.
Br. J. Ophthalmol. 2005;89:847-850.
ABSTRACT | FULL TEXT  

Genetic Polymorphisms in the Angiotensin II Receptor Gene and Their Association with Open-Angle Glaucoma in a Japanese Population
Hashizume et al.
IOVS 2005;46:1993-2001.
ABSTRACT | FULL TEXT  

Intraocular pressure in the Middle East
Hennis
Br. J. Ophthalmol. 2005;89:647-648.
FULL TEXT  

Glaucoma and its treatment: A review
Lee and Higginbotham
Am J Health Syst Pharm 2005;62:691-699.
ABSTRACT | FULL TEXT  

High-dose radiation with bone marrow transfer prevents neurodegeneration in an inherited glaucoma
Anderson et al.
Proc. Natl. Acad. Sci. USA 2005;102:4566-4571.
ABSTRACT | FULL TEXT  

Screening for Primary Open-Angle Glaucoma in the Primary Care Setting: An Update for the US Preventive Services Task Force
Fleming et al.
Ann Fam Med 2005;3:167-170.
ABSTRACT | FULL TEXT  

Relative Change in Diurnal Mean Ocular Perfusion Pressure: A Risk Factor for the Diagnosis of Primary Open-Angle Glaucoma
Sehi et al.
IOVS 2005;46:561-567.
ABSTRACT | FULL TEXT  

Variants in Optineurin Gene and Their Association with Tumor Necrosis Factor-{alpha} Polymorphisms in Japanese Patients with Glaucoma
Funayama et al.
IOVS 2004;45:4359-4367.
ABSTRACT | FULL TEXT  

Persistency and treatment failure in newly diagnosed open angle glaucoma patients in the United Kingdom
Zhou et al.
Br. J. Ophthalmol. 2004;88:1391-1394.
ABSTRACT | FULL TEXT  

Neural Losses Correlated with Visual Losses in Clinical Perimetry
Harwerth et al.
IOVS 2004;45:3152-3160.
ABSTRACT | FULL TEXT  

The Ocular Hypertension Treatment Study: Topical Medication Delays or Prevents Primary Open-angle Glaucoma in African American Individuals
Higginbotham et al.
Arch Ophthalmol 2004;122:813-820.
ABSTRACT | FULL TEXT  

Prevalence of Open-Angle Glaucoma Among Adults in the United States
The Eye Diseases Prevalence Research Group
Arch Ophthalmol 2004;122:532-538.
ABSTRACT | FULL TEXT  

The Relationship between Standard Automated Perimetry and GDx VCC Measurements
Reus and Lemij
IOVS 2004;45:840-845.
ABSTRACT | FULL TEXT  

Intraobserver and interobserver reproducibility in the evaluation of ultrasonic pachymetry measurements of central corneal thickness
Miglior et al.
Br. J. Ophthalmol. 2004;88:174-177.
ABSTRACT | FULL TEXT  

Do selective topical {beta} antagonists for glaucoma have respiratory side effects?
Kirwan et al.
Br. J. Ophthalmol. 2004;88:196-198.
ABSTRACT | FULL TEXT  

The Case Against Glaucoma Drainage Implant Surgery in Patients With a Poor Prognosis for Standard Filtering Procedure
Higginbotham
Arch Ophthalmol 2004;122:105-107.
FULL TEXT  

Prospective Study of Cigarette Smoking and the Risk of Primary Open-angle Glaucoma
Kang et al.
Arch Ophthalmol 2003;121:1762-1768.
ABSTRACT | FULL TEXT  

Important Causes of Visual Impairment in the World Today
Congdon et al.
JAMA 2003;290:2057-2060.
FULL TEXT  

Gene Therapy with Brain-Derived Neurotrophic Factor As a Protection: Retinal Ganglion Cells in a Rat Glaucoma Model
Martin et al.
IOVS 2003;44:4357-4365.
ABSTRACT | FULL TEXT  

A Statistical Model for the Evaluation of Sensory Tests in Glaucoma, Depending on Optic Disc Damage
Stroux et al.
IOVS 2003;44:2879-2884.
ABSTRACT | FULL TEXT  

'This added to my multiple myopia'
Irwig
BMJ 2003;326:1336-1336.
FULL TEXT  

Human Lens Epithelial Cell Damage and Stimulation of Their Secretion of Chemical Mediators by Benzalkonium Chloride Rather Than Latanoprost and Timolol
Goto et al.
Arch Ophthalmol 2003;121:835-839.
ABSTRACT | FULL TEXT  

Does Benzalkonium Chloride Cause Cataract?
Brandt
Arch Ophthalmol 2003;121:892-893.
FULL TEXT  

Treatment of raised intraocular pressure and prevention of glaucoma
Wormald
BMJ 2003;326:723-724.
FULL TEXT  

New topical drugs for open-angle glaucoma
DTB 2003;41:12-14.
ABSTRACT | FULL TEXT  

Factors for Glaucoma Progression and the Effect of Treatment: The Early Manifest Glaucoma Trial
Leske et al.
Arch Ophthalmol 2003;121:48-56.
ABSTRACT | FULL TEXT  

Impact of Intraocular Pressure Reduction on Glaucoma Progression
Lichter
JAMA 2002;288:2607-2608.
FULL TEXT  

Expectations From Clinical Trials: Results of the Early Manifest Glaucoma Trial
Lichter
Arch Ophthalmol 2002;120:1371-1372.
FULL TEXT